References
Inspire Pharmaceuticals. Inspire Pharmaceuticals Announces FDA Acceptance Of Diquafosol NDA for Filing. Media Release: 9 Sep 2003. Available from URL: http://www.inspirepharm.com
Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals’ Diquafosol NDA Granted Priority Review by the FDA. Media Release: 31 Jul 2003. Available from URL: http://www.nrpeuro.com
Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals, Inc. reports positive results for novel therapeutic for dry eye disease. Media Release: [2 pages], 11 May 1999
Evans R, Johnson F, Kellerman D, et al. Aerosolized INS365 for COPD: enhanced deposition and clearance using the AERx delivery system. American Journal of Respiratory and Critical Care Medicine 161 (Suppl.): 815, Part 2, Mar 2000
Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals reports positive phase I results for INS365; announces new clinical collaboration with cystic fibrosis foundation. Media Release: [2 pages], 17 Oct 1998
Kellerman DJ, Bennett WD, Zeman KL, et al. Dose response relationship of the P2Y2 agonist INS365 on mucociliary clearance in smokers. Journal of Allergy and Clinical Immunology 107 (Abstr. Suppl.): 164–165, Feb 2001
Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals, Inc. presents positive phase II data for INS365 ophthalmic for dry eye, and launches first phase I/II clinical trial for INS37217 ophthalmic for retinal detachment. Media Release: [3 pages], 3 May 2001. Available from URL: http://www.inspirepharm.com
Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals Announces Results of Second Phase III Trial of INS365 Ophthalmic for The Treatment of Dry Eye. Media Release: 18 Jun 2002. Available from URL: http://www.inspirepharm.com
Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals Announces Timing of Dry Eye NDA Based on Pre-NDA Meeting with the FDA — Also Provides Guidance on 2003 Revenues. Media Release: 7 Jan 2003. Available from URL: http://www.inspirepharm.com
Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals Announces Results of Phase IIIb Study in Dry Eye. Media Release: 13 Aug 2003. Available from URL: http://www.inspirepharm.com
Rights and permissions
About this article
Cite this article
Diquafosol. Drugs R&D 4, 359–362 (2003). https://doi.org/10.2165/00126839-200304060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200304060-00005